This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

SSRI (SSRIs) in the menopause

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • selective serotonin and noradrenaline reuptake inhibitors (SSRIs & SNRIs) (1)
    • SSRIs as an alternative to HRT - general principles
      • in general baseline effectiveness 20-50%
      • class effect of SSRIs are of antidepressant benefit and improved quality of life
      • class effect of SSRIs include initial side effects such as nausea, dizziness, shortterm aggravation of base-line anxiety and mood, so encourage your patient to persevere and if necessary take on alternative days, even ½ tablet
      • class effect of all SSRIs is sexual dysfunction- no one SSRI is better than any other in this respect and there is great individual variation in response
      • some SSRIs (paroxetine, fluoxetine, paroxetine, sertraline) interact with cytochrome P450, so avoid in patients on Tamoxifen

    • SSRI’s such as paroxetine (12.5-25mg daily) has shown to reduce flushes in 50%, while fluoxetine (20mg daily) has also been reported to reduce in 60% (2) (1)
      • paroxetine
  • dosage 10-20mg - baseline improvement 50-60%. Paroxetine has best evidence for vaso-motor control and has maximal benefit achieved at 10mg
  • class effect of SSRIs are of antidepressant benefit and improved quality of life
  • interacts with enzyme cytochrome P450 (CYN10) thereby rendering Tamoxifen less effective

    • fluoxetine (1)
      • dosage 20mg - baseline effectiveness 10-20mg
      • class effect of SSRIs are of antidepressant benefit and improved quality of life
      • like Paroxetine should be avoided in patients taking Tamoxifen

    • citalopram (Escitalopram) (1)
      • dosage 20mg - baseline benefit 40-50%
      • class effect of SSRIs are of antidepressant benefit and improved quality of life
      • much less effect on enzyme cytochrome P450 so can be used in patients on Tamoxifen

    • sertraline (1)
      • dosage 25-50mg - baseline benefit - little information
      • sertraline is the best anti-anxiety SSRI
      • least well tolerated with an increase in anxiety at the outset. Interacts with cytochrome P450, so avoid in patients on Tamoxifen
  • SNRIs (venlafaxine) (1) - dosage 37.5mg -150mg sustained release preparations recommended; baseline benefit quoted 20-66%
    • often poorly tolerated at outset with dizziness and other associated SSRI side effects including sexual dysfunction, slow titration may be the answer
    • no interaction with cytochrome P450 so may be safest choice for patients on Tamoxifen

Notes (3):

  • Finding Lasting Answers for Symptoms and Health (i.e., MsFLASH) studies revealed a significant reduction in hot flashes of 54% for escitalopram, 48% for estradiol, and 49% for venlafaxine
    • sexual desire was minimally better with estradiol than SSRI treatment, while venlafaxine was better than estradiol for therapy of anorgasmia, pain, and vaginal dryness
    • improvement in sleep quality and duration was minimally and equally improved with both forms of therapy
  • in a separate study, paroxetine 7.5 mg daily was shown to improve hot flashes without weight gain or sexual dysfunction

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.